CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI

July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3. Cardiac Interventions TODAY | July 8, 2024 Read on line CellProthera and Alfresa Holdings sign a Memorandum of Understanding to Advance Phase 3 Development and Future wholesale distribution of ProtheraCytes® in Japan 11 August, 2026 Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack? 02 July, 2026 CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality 02 June, 2026

The release as fetched from its publisher. cellprothera.com ↗